{"id":82,"date":"2018-10-05T19:40:40","date_gmt":"2018-10-05T19:40:40","guid":{"rendered":"https:\/\/bridgebioprod.wpengine.com\/?p=82"},"modified":"2022-06-23T12:29:54","modified_gmt":"2022-06-23T16:29:54","slug":"eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/","title":{"rendered":"Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation"},"content":{"rendered":"\r\n<p>SAN FRANCISCO, Oct. 05, 2018 (GLOBE NEWSWIRE) &#8212; Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) will be announced in a late-breaking featured science oral presentation at this year\u2019s American Heart Association (AHA) Scientific Sessions.<\/p>\r\n\r\n\r\n\r\n<p>Daniel Judge, M.D., professor in the division of cardiology at the Medical University of South Carolina, will discuss the data in a presentation entitled \u201cSafety, Tolerability and Transthyretin Stabilization by AG10: A Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients with Transthyretin Amyloid Cardiomyopathy and NYHA Class II\/III Heart Failure\u201d as part of the New Trials in Cardiovascular Care oral session at 9:00 AM CT on November 10, 2018.<\/p>\r\n\r\n\r\n\r\n<p>Eidos will host an investor conference call and webcast following the presentation to highlight details of the Phase 2 data. Details for the call and webcast will be announced at a later date.<\/p>\r\n\r\n\r\n\r\n<h4 class=\"wp-block-heading\">About AG10<\/h4>\r\n\r\n\r\n\r\n<p>AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. AG10 is currently being examined in an open-label extension of a Phase 2 clinical trial in patients with ATTR cardiomyopathy.<\/p>\r\n\r\n\r\n\r\n<p>AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a \u201crescue mutation\u201d because it has been shown to prevent ATTR in individuals carrying pathogenic, or disease-causing, mutations in the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the \u201csuper-stabilizing\u201d properties of this rescue mutation.<\/p>\r\n\r\n\r\n\r\n<h4 class=\"wp-block-heading\">About Eidos Therapeutics<\/h4>\r\n\r\n\r\n\r\n<p>Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). For more information, please visit <a href=\"https:\/\/www.eidostx.com\/\">www.eidostx.com.<\/a><\/p>\r\n\r\n\r\n\r\n<p>Media Contact:<br \/>Carolyn Hawley<br \/>Canale Communications 619-849-5382<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZP0Vte4MBhZj7aP_N0N-rozeFYcvYt0ZDcbW6vewXVuPKBLz1kb7vAims5CQAxQ93fjRunyXUDnbE_KrVcHcYxiyOg2FWz7t2JFaVxzuxCE%3D\">Carolyn@canalecomm.com<\/a><br \/>Investor Contact:<br \/>Alex Gray<br \/>Burns McClellan 212-213-0006<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9CsgJtqTpBfq0OnpkJL5qynmegQ3n0bhJybbFFywfCKRslLUma6fLkC2U2Q7Ba1-N9N_CbOcd-ubjcOSPaW85g%3D%3D\">agray@burnsmc.com<\/a><\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Oct. 05, 2018 (GLOBE NEWSWIRE) &#8212; Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) will be announced in a late-breaking featured science oral presentation at this year\u2019s American Heart Association (AHA) Scientific Sessions. Daniel Judge, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-82","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"meta_short_title":"Eidos Therapeutics to Present Phase 2 Data for AG10","meta_description":"Eidos Therapeutics\u2019 Phase 2 clinical trial results studying AG10 with TTR ATTR-CM will be presented at the American Heart Association Scientific Sessions.","meta_share_image":false,"external_link":"","external_link_source":"","presentation":"","people":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Eidos to Present Phase 2 Data for AG10 | BridgeBio<\/title>\n<meta name=\"description\" content=\"Eidos announced that results of its Phase 2 clinical trial studying AG10 in subjects with ATTR-CM will be announced at this year\u2019s AHA Scientific Sessions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eidos to Present Phase 2 Data for AG10 | BridgeBio\" \/>\n<meta property=\"og:description\" content=\"Eidos announced that results of its Phase 2 clinical trial studying AG10 in subjects with ATTR-CM will be announced at this year\u2019s AHA Scientific Sessions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-05T19:40:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T16:29:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Julianne Twining\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Julianne Twining\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/\",\"url\":\"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/\",\"name\":\"Eidos to Present Phase 2 Data for AG10 | BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2018-10-05T19:40:40+00:00\",\"dateModified\":\"2022-06-23T16:29:54+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/f567122d9069e4cac0b57561cb43f962\"},\"description\":\"Eidos announced that results of its Phase 2 clinical trial studying AG10 in subjects with ATTR-CM will be announced at this year\u2019s AHA Scientific Sessions.\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/f567122d9069e4cac0b57561cb43f962\",\"name\":\"Julianne Twining\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/925ac813b5977675ca06cc772ee2d3fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/925ac813b5977675ca06cc772ee2d3fe?s=96&d=mm&r=g\",\"caption\":\"Julianne Twining\"},\"url\":\"https:\/\/bridgebio.com\/author\/julianne\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eidos to Present Phase 2 Data for AG10 | BridgeBio","description":"Eidos announced that results of its Phase 2 clinical trial studying AG10 in subjects with ATTR-CM will be announced at this year\u2019s AHA Scientific Sessions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/","og_locale":"en_US","og_type":"article","og_title":"Eidos to Present Phase 2 Data for AG10 | BridgeBio","og_description":"Eidos announced that results of its Phase 2 clinical trial studying AG10 in subjects with ATTR-CM will be announced at this year\u2019s AHA Scientific Sessions.","og_url":"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/","og_site_name":"BridgeBio","article_published_time":"2018-10-05T19:40:40+00:00","article_modified_time":"2022-06-23T16:29:54+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Julianne Twining","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Julianne Twining","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/","url":"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/","name":"Eidos to Present Phase 2 Data for AG10 | BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2018-10-05T19:40:40+00:00","dateModified":"2022-06-23T16:29:54+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/f567122d9069e4cac0b57561cb43f962"},"description":"Eidos announced that results of its Phase 2 clinical trial studying AG10 in subjects with ATTR-CM will be announced at this year\u2019s AHA Scientific Sessions.","breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/f567122d9069e4cac0b57561cb43f962","name":"Julianne Twining","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/925ac813b5977675ca06cc772ee2d3fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/925ac813b5977675ca06cc772ee2d3fe?s=96&d=mm&r=g","caption":"Julianne Twining"},"url":"https:\/\/bridgebio.com\/author\/julianne\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/82"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=82"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/82\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=82"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=82"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=82"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}